Study the Effect of Probiotic Supplementation on Trimethylamine-N-Oxide Plasma Level in Hemodialysis Patients - Trial NCT06421883
Access comprehensive clinical trial information for NCT06421883 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Al-Azhar University and is currently Enrolling by invitation. The study focuses on End Stage Renal Disease. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Al-Azhar University
Timeline & Enrollment
Phase 2/3
Mar 15, 2024
Oct 15, 2024
Primary Outcome
change in Trimethylamine-N-Oxide Plasma Level
Summary
The goal of this clinical trial is to learn if probiotic has an effect on
 Trimethylamine-N-Oxide Plasma Level in plasma, which represent strong risk factor for
 Atherosclerosis in end stage renal disease patients who undergoing hemodialysis the main
 questions to answer are : Does probiotic lower Trimethylamine-N-Oxide concentration? does
 probiotic participating in decreasing risk of atherosclerosis in end stage renal disease
 patients undergoing hemodialysis ? research will compare between patients who are taking
 probiotic and control group (taking no drug) participants will take probiotic for 3 months
 visit the clinic once every 2 weeks for checkups and tests
 
 All Patients will be subjected to the following:
 
 1. Informed consent.
 
 2. Demographics and history taking: Using Patient Data sheet.
 
 3. Laboratory evaluation including:
 
 Kidney function tests: blood urea,serum creatinine, albumin ,uric acid. Complete blood count
 (CBC).
 
 C-reactive protein (CRP).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06421883
Non-Device Trial